Emergent BioSolutions Issues Outlook

(RTTNews) - Emergent BioSolutions Inc. (EBS) Sunday provided outlook for the full year 2014 and 2015.

For the full year 2014, the company expects earnings of $0.97 to $1.02 per basic share, adjusted earnings of $1.42 to $1.47 per share and revenues of $445 million to $450 million.

The company said the outlook reflects the continued robust BioThrax sales, accounting for approximately $246 million, an expansion of the Biodefense division, initial revenues from the Biosciences product portfolio resulting from the Cangene acquisition, and success in partnering one of the Biosciences preclinical assets.

For the full year 2015, the company expects earnings of $50 million to $60 million, adjusted net income of $60 milion to $70 million and revenues of $510 million to $540 million.

For the first quarter of 2015, the company anticipates total revenues of $90 million to $105 million.